Cytodyn Inc (CYDY)

[Mymani]

“Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents as part of standard-of-care”

Clinicaltrials.gov shows under LL ‘s s2c trial

It will be interesting to see if we actually enrolled any such patients and actually saw their primary and secondary outcomes improve.